Roche Inks $549M Deal To License 'Superbug' Antibiotic

Law360, New York (November 4, 2013, 2:43 PM EST) -- Biotech giant Roche will pay up to 500 million Swiss francs ($549 million) to Polyphor Ltd. for an exclusive worldwide license agreement to develop and market its drug that targets an antibiotic-resistant "superbug" bacteria often found in hospitals, according to a statement.

Roche, under the deal terms, will make an initial payment of 35 million Swiss francs followed by payments based on development, regulatory and commercial milestones of the POL7080 antibiotic, according to a statement. Polyphor will also receive tiered royalties on product sales and will...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.